Patient Support

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, discusses "Enhancing Patient Access and Support Through Technology: A Comprehensive Assessment," and upcoming industry challenges.

A session provides considerations for manufacturers during development, rollouts, and implementation, specifically as it pertains to the HSSP perspective.

Kevin O’Meara discusses Patient-Cetric 3.0 breakout session and the challenges of drug manufactures implementing Direct-to-Patient models.

A case study explores a way to potentially transform commercial organizations, while driving revenue growth.

A panel uncovers how distribution channels are aligning commercialization efforts.

Filling the gaps in the patient journey within an increasingly complex data environment.

A guide to overcoming the top obstacles facing patient services programs today.

Is the potential of a more formal policy integration for health issues and disease prevention a scary suggestion or a good idea?

While the program could be a good option for many, it's not a panacea.

A qualitative analysis consisting of patients, care partners, and oncology clinicians measures the sources of time burdens, along with how these impact various individuals.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chase Feiger, MD, co-founder, Ostro, outlines the trends he expects to see over the next 10-15 years when it comes to the intersection of AI and life sciences.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chase Feiger, MD, co-founder, Ostro, discusses the value of AI technology when it comes to tackling digital commercialization challenges.

The media company utilized CMS data and worked with Medicare experts to pinpoint qualities that were highly valued to consumers.

Could health system changes that improve patient access to medication have a positive effect on societal welfare?

What are their satisfaction rates when it comes to telemedicine visits?

The collaboration ultimately benefits oncology patients, as life science companies will be able to access their cancer journey data more efficiently.

By 2050, study estimates that cancer incidence and mortality rates will nearly triple in low-Human Development Index countries, highlighting an urgent need for enhanced global cancer prevention, early detection, and treatment strategies to address growing disparities.

With today's pharmacy landscape shaken by unprecedented and wider disruption to healthcare support and delivery, community and independent entities strive to remain an integral cog in the mix.

With great power comes great responsibility. In this case, tackling these obstacles is vital to making sure that the positives of GLP-1s are not outweighed by the downfalls of improper waste disposal.

A panel dives into the current and future outlook of healthcare policies.

A cohort study aims to connect the dots between incident AWVs among older adults with the first ADRD or MCI diagnosis who receive Medicare fee-for-service benefits.

A deep dive into the future of patient service programs and the value of transparency throughout the process.

In this video interview with Pharma Commerce Editor Nicholas Saraceno, John Stefankiewicz, VP of Analytics, Cencora, describes the value of advocacy and other solutions in under-served areas.

In this video interview with Pharma Commerce Editor Nicholas Saraceno, John Stefankiewicz, VP of Analytics, Cencora, details why these pharmacy deserts have become so widespread.

In this video interview with Pharma Commerce Editor Nicholas Saraceno, Jenni Zilka, SVP, community & specialty pharmacy and president, Good Neighbor Pharmacy, clarifies the meaning behind pharmacy deserts, along with reasons for their increase in prominence.

When it comes to navigating the complex clinical and commercial landscape for specialty drugs—including hurdles in access to these critical but costly therapies—today’s specialty pharmacies are bringing more skills and services to the table.

Are these statistical characteristics—along with social determinants of health—associated with denials of preventive care claims?

Why looming benefit changes—and the resulting unintended consequences—are a concern for patients.

The provider’s partnership with AI innovator Odaia offers deeper, broader insights to HCP activity.

A study examines if this PCP-large health system dynamic impacts patient outcomes.